Zhejiang Hisoar Pharmaceutical Co Ltd (002099) - Total Liabilities
Based on the latest financial reports, Zhejiang Hisoar Pharmaceutical Co Ltd (002099) has total liabilities worth CN¥2.17 Billion CNY (≈ $317.08 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 002099 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Zhejiang Hisoar Pharmaceutical Co Ltd - Total Liabilities Trend (2003–2024)
This chart illustrates how Zhejiang Hisoar Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Zhejiang Hisoar Pharmaceutical Co Ltd (002099) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Zhejiang Hisoar Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Hisoar Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Luoman Lighting Technologies Inc.
SHG:605289
|
China | CN¥1.55 Billion |
|
Zotye Automobile Co Ltd
SHE:000980
|
China | CN¥3.35 Billion |
|
TTW Public Company Limited
BK:TTW
|
Thailand | ฿6.82 Billion |
|
Henan Thinker Automation
SHG:603508
|
China | CN¥315.73 Million |
|
Yapp Automotive Systems Co Ltd
SHG:603013
|
China | CN¥2.44 Billion |
|
Wuhan East Lake High Technology Group Co Ltd
SHG:600133
|
China | CN¥8.69 Billion |
|
Pabrik Kertas Tjiwi Kimia Tbk
JK:TKIM
|
Indonesia | Rp988.48 Million |
|
Nolato AB (publ)
ST:NOLA-B
|
Sweden | Skr3.90 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Zhejiang Hisoar Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002099 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Hisoar Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Hisoar Pharmaceutical Co Ltd (2003–2024)
The table below shows the annual total liabilities of Zhejiang Hisoar Pharmaceutical Co Ltd from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.32 Billion ≈ $340.11 Million |
+21.16% |
| 2023-12-31 | CN¥1.92 Billion ≈ $280.72 Million |
-16.16% |
| 2022-12-31 | CN¥2.29 Billion ≈ $334.83 Million |
+20.03% |
| 2021-12-31 | CN¥1.91 Billion ≈ $278.95 Million |
+43.71% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.11 Million |
+29.70% |
| 2019-12-31 | CN¥1.02 Billion ≈ $149.66 Million |
-37.82% |
| 2018-12-31 | CN¥1.64 Billion ≈ $240.69 Million |
-29.25% |
| 2017-12-31 | CN¥2.32 Billion ≈ $340.21 Million |
+8.88% |
| 2016-12-31 | CN¥2.14 Billion ≈ $312.46 Million |
+69.73% |
| 2015-12-31 | CN¥1.26 Billion ≈ $184.09 Million |
+27.24% |
| 2014-12-31 | CN¥988.73 Million ≈ $144.68 Million |
-33.05% |
| 2013-12-31 | CN¥1.48 Billion ≈ $216.09 Million |
+25.15% |
| 2012-12-31 | CN¥1.18 Billion ≈ $172.67 Million |
+69.01% |
| 2011-12-31 | CN¥698.17 Million ≈ $102.16 Million |
+39.00% |
| 2010-12-31 | CN¥502.28 Million ≈ $73.50 Million |
+15.60% |
| 2009-12-31 | CN¥434.48 Million ≈ $63.58 Million |
-6.68% |
| 2008-12-31 | CN¥465.58 Million ≈ $68.13 Million |
+13.09% |
| 2007-12-31 | CN¥411.69 Million ≈ $60.24 Million |
+2.24% |
| 2006-12-31 | CN¥402.66 Million ≈ $58.92 Million |
+2.26% |
| 2005-12-31 | CN¥393.76 Million ≈ $57.62 Million |
+54.20% |
| 2004-12-31 | CN¥255.35 Million ≈ $37.37 Million |
-7.94% |
| 2003-12-31 | CN¥277.36 Million ≈ $40.59 Million |
-- |
About Zhejiang Hisoar Pharmaceutical Co Ltd
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products. It also provides dyestuff, and intermediates of dyestuff and pigment; and manufactures environmental protection related equipment, medical… Read more